bevacizumab,atezolizumab
roche
['imbrave 050', 'kudos']
kudos to imbrave 050 for presenting qol data at #asco23 in addition to efficacy data but why was crossover not mandated and only permitted? didn t you prove that the same regimen improved os as 1l for metastatic disease? shouldn t you mandate crossover then? #commonsense 
Personal account. Med Onc. Associate Prof. @queensoncology @QueensuPHS. #cancerpolicy #cancergroundshot. Pubs: https://t.co/FTRPKNykq3 Talks- https://t.co/anav3AIZjO